Univariate analysis comparing patient demographic characteristics, pathologic features and stage between endometrial cancers staged in the 2 years before the COVID-19 pandemic and in the first year of the pandemic
| Variable | No. (%)of cases* | Standardized difference | Stochastic dominance | OR (95% CI) | |
|---|---|---|---|---|---|
| 2 years before pandemic n = 372 | First year of pandemic n = 113 | ||||
| No. of cases per 30 d, mean | 15.3 | 9.3 | NA | ||
| Age, median (IQR), yr | 64 (59–68) | 63 (58–67) | 0.081 | – | NA |
| Histologic subtype | – | ||||
| Acinar adenocarcinoma | 349 (93.8) | 109 (96.5) | 0.123 | 1.80 (0.61–5.31) | |
| Acinar adenocarcinoma with mixed features | 23 (6.2) | 4 (3.5) | 0.56 (0.19–1.65) | ||
| Gleason Grade Group† | |||||
| 1 + 2 | 274 (73.7) | 79 (69.9) | 0.083 | 0.519 | 0.83 (0.52–1.32) |
| 3–5 | 98 (26.3) | 34 (30.1) | 1.21 (0.76–1.92) | ||
| Intraductal carcinoma | 102 (27.4) | 37 (32.7) | 0.116 | 0.473 | 1.29 (0.82–2.03) |
| Lymphovascular invasion | 34 (9.1) | 14 (12.4) | 0.105 | 0.516 | 1.41 (0.73–2.74) |
| Perineural invasion | 329 (88.4) | 105 (92.9) | 0.155 | 0.478 | 1.72 (0.78–3.77) |
| Margin status | |||||
| Negative | 249 (66.9) | 73 (64.6) | – | 0.503 | 0.90 (0.58–1.40) |
| Limited positive | 59 (15.9) | 25 (22.1) | 1.50 (0.89–2.53) | ||
| Nonlimited positive | 64 (17.2) | 15 (13.3) | 0.74 (0.40–1.35) | ||
| Stage | |||||
| I + II‡ | 161 (43.3) | 44 (38.9) | – | 0.525 | NA |
| III | 184 (49.5) | 59 (52.2) | |||
| IV | 27 (7.3) | 10 (8.8) | |||